Nifty Pharma
NSESector20 companies
- P/EPrice to earnings of an index. The index's P/E as the exchange publishes it with the close: its members' market value divided by their profit over the last twelve months, each member counted as the index weighs it.
- 39.18
- P/BPrice to book of an index. The index's P/B as the exchange publishes it: its members' market value divided by their net worth, the assets they own less everything they owe.
- 4.77
- Dividend yieldDividend yield of an index. The index's dividend yield as the exchange publishes it: dividends its members paid over the last twelve months as a percentage of their market value.
- 0.59%
- 1MOne-month return of an index. The latest close against the close a month earlier, on the same date or the last trading day before it, as a percentage.
- −6.71%
- 3MThree-month return of an index. The latest close against the close three months earlier, on the same date or the last trading day before it, as a percentage.
- −1.26%
- 1YOne-year return of an index. The latest close against the close a year earlier, on the same date or the last trading day before it, as a percentage.
- +12.67%
P/E against its own past
Where today's P/E sits among every trading day of each window: the dot is today, the tick the middle day.
P/E at each month's last trading day, and on 23 Oct 2026
What the Nifty Pharma companies earned
Each quarter against the same quarter a year earlier, added up over today's members that filed both. A quarter fewer than 60% of them filed is left out.
- Revenue growthRevenue growth, against a year earlier. Revenue of the quarter to Jun 2026 against the same quarter a year earlier, added up over the 20 companies that filed both.
- +15.3%quarter to Jun 2026
- Profit growthProfit growth, against a year earlier. Profit of the quarter to Jun 2026 against the same quarter a year earlier, added up over the 20 companies that filed both and made a profit a year earlier.
- +6.0%quarter to Jun 2026
- Filed the quarterCompanies that filed the quarter. How many of the index's 20 listed companies have filed results for the quarter to Jun 2026; the growth figures are theirs.
- 20of 20
- Median ROCEMedian return on capital employed. The middle figure of the 20 companies' ROCE for the year to Mar 2026, half above and half below. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them.
- 15.8%year to Mar 2026
Growth against the same quarter a year earlier, per cent
- Revenue growth
- Profit growth
- Loss
Revenue grew against a year earlier in 12 of the 12 quarters shown.Fastest profit growth +48.5%, quarter to Mar 2024.
The largest companies
The 12 largest companies in the Nifty Pharma, each sized by its market cap.
Market cap, ₹ crore
- Sun Pharmaceutical Industries₹4,19,404 Cr
- Divi's Laboratories₹2,37,594 Cr
- Torrent Pharmaceuticals₹1,72,094 Cr
- Zydus Lifesciences₹1,12,658 Cr
- Cipla₹1,08,093 Cr
- Laurus Labs₹1,06,442 Cr
- Dr. Reddy's Laboratories₹1,02,624 Cr
- Mankind Pharma₹91,390 Cr
- Aurobindo Pharma₹90,432 Cr
- Lupin₹88,207 Cr
- Glenmark Pharmaceuticals₹61,147 Cr
- Alkem Laboratories₹59,149 Cr
Companies in the Nifty Pharma
Largest first, by market cap.
Sun Pharmaceutical IndustriesSUNPHARMA · Pharmaceuticals & Biotechnology₹1,748.00−0.57%₹4,19,404 Cr34.716.9%0.92%+3.4%
Divi's LaboratoriesDIVISLAB · Pharmaceuticals & Biotechnology₹8,950.00−2.31%₹2,37,594 Cr81.220.8%0.34%+36.3%
Torrent PharmaceuticalsTORNTPHARM · Pharmaceuticals & Biotechnology₹4,524.40−1.97%₹1,72,094 Cr78.911.4%0.84%+25.2%
Zydus LifesciencesZYDUSLIFE · Pharmaceuticals & Biotechnology₹1,129.40−0.49%₹1,12,658 Cr25.015.9%0.09%+11.9%
CiplaCIPLA · Pharmaceuticals & Biotechnology₹1,338.00+0.53%₹1,08,093 Cr32.111.6%0.97%−18.7%
Laurus LabsLAURUSLABS · Pharmaceuticals & Biotechnology₹1,970.00−1.62%₹1,06,442 Cr97.419.8%0.10%+110.8%
Dr. Reddy's LaboratoriesDRREDDY · Pharmaceuticals & Biotechnology₹1,229.50−0.77%₹1,02,624 Cr31.96.8%0.65%−3.9%
Mankind PharmaMANKIND · Pharmaceuticals & Biotechnology₹2,212.60−2.77%₹91,390 Cr44.612.8%None−9.7%
Aurobindo PharmaAUROPHARMA · Pharmaceuticals & Biotechnology₹1,571.70−2.43%₹90,432 Cr24.411.5%None+43.0%
LupinLUPIN · Pharmaceuticals & Biotechnology₹1,928.90+0.36%₹88,207 Cr16.028.2%0.93%−0.6%
Glenmark PharmaceuticalsGLENMARK · Pharmaceuticals & Biotechnology₹2,166.60−1.45%₹61,147 Cr34.039.8%0.12%+17.1%
Alkem LaboratoriesALKEM · Pharmaceuticals & Biotechnology₹4,947.00−1.33%₹59,149 Cr27.416.5%1.07%−10.6%
Abbott IndiaABBOTINDIA · Pharmaceuticals & Biotechnology₹25,030.00−1.30%₹53,187 Cr32.939.7%2.62%−16.9%
BioconBIOCON · Pharmaceuticals & Biotechnology₹323.50−2.06%₹52,721 Cr106.42.9%0.15%−10.7%
IPCA LaboratoriesIPCALAB · Pharmaceuticals & Biotechnology₹1,953.30+2.62%₹49,556 Cr37.817.6%0.31%+53.0%
Gland PharmaGLAND · Pharmaceuticals & Biotechnology₹2,826.80−0.83%₹46,645 Cr41.312.4%0.71%+46.3%
Ajanta PharmaAJANTPHARM · Pharmaceuticals & Biotechnology₹3,283.90+0.41%₹41,035 Cr36.227.2%1.83%+36.0%
Sai Life SciencesSAILIFE · Pharmaceuticals & Biotechnology₹1,395.30−0.04%₹29,639 Cr81.918.7%None+56.4%
WockhardtWOCKPHARMA · Pharmaceuticals & Biotechnology₹1,801.70−2.90%₹29,276 Cr71.67.4%None+32.6%
Piramal PharmaPPLPHARMA · Pharmaceuticals & Biotechnology₹191.07−2.01%₹25,438 Cr–1.1%None−6.2%
Funds that follow the Nifty Pharma
2 funds with the Nifty Pharma as the benchmark they measure themselves against, from each fund's latest monthly report.
About the Nifty Pharma
An index of 20 companies: it shows how they have moved together, and its P/E is what the market pays for a year of their profit.
- Published by
- NSE
- Kind
- Sector
- CompaniesCompanies in an index. How many companies the index holds on its current list, which the exchange revises from time to time.
- 20
- List last changed
- 8 Sep 2026
- Above 200-day averageMembers above their 200-day average. The share of the index's members whose latest close is above their own average close of the last 200 trading days; members listed too recently to have one are left out.
- 11 of 20